| Literature DB >> 9012475 |
J C Kucharczuk1, B Randazzo, M Y Chang, K M Amin, A A Elshami, D H Sterman, N P Rizk, K L Molnar-Kimber, S M Brown, A R MacLean, L A Litzky, N W Fraser, S M Albelda, L R Kaiser.
Abstract
Modified, nonneurovirulent herpes simplex viruses (HSVs) have shown promise in the treatment of brain tumors. However, HSV-1 can infect and lyse a wide range of cell types. In this report, we show that HSV-1716, a mutant lacking both copies of the gene coding ICP-34.5, can effectively treat a localized i.p. malignancy. Human malignant mesothelioma cells supported the growth of HSV-1716 and were efficiently lysed in vitro. i.p. injection of HSV-1716 into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy without dissemination or persistence after i.p. injection into SCID mice bearing human tumors. These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of nonneuronal origin such as malignant mesothelioma.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9012475
Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701